Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > BUSINESS
BUSINESS
- InCROM Subsidiary in Shanghai Set to Become Subsidiary of Chinese Pharma Giant, Aims for Business Expansion
September 10, 2013
- Wholesalers to Stress that Medical Institutions Will Not Have to Incur Any Losses Due to Consumption Tax Hike
September 10, 2013
- Novartis AG Takes Retraction of JIKEI Paper “Seriously”; Problems Partly Traced to “Limited Understanding” about Investigator-Led Trials
September 9, 2013
- Shionogi Launches Irtra Combination Tablets LD/HD
September 9, 2013
- Novartis Appoints Former AbbVie Exec to Lead Medical Scientific Affairs
September 6, 2013
- Otsuka Holdings President Has High Hopes for Rapid Lead Compound Discovery
September 6, 2013
- Otsuka to Buy US Biotech Firm Astex for US$886 Million
September 6, 2013
- Takeda Mulls Taking Stab at Generic Biz in Japan via ASKA
September 6, 2013
- General Logistics Companies Increasing Their Investment in Field of Drug Distribution; Opening More Specialized Warehouses
September 6, 2013
- Edoxaban Shows Non-Inferiority to Warfarin for VTE: Daiichi Sankyo
September 6, 2013
- Will Once-weekly Formulations and New Products Help GLP-1 Receptor Agonists Break Out of Their Slump?
September 6, 2013
- Teva Japan to Pursue High-Value-Added Generics, Eyes Partnerships with Japanese Companies: Chairman Krinsky
September 5, 2013
- Teva Pharma Japan Aims for the Top in Japan Generic Market by 2018: President
September 5, 2013
- Kyowa Kirin Ties Up with Ultragenyx for XLH Treatment KRN23
September 5, 2013
- ASKA to Launch Generic Biz Unit; Takeda’s Yonezawa to Take Helm
September 4, 2013
- Otsuka Paid 20 Billion Yen to Healthcare Professionals in FY2012, 5.4 Billion Yen for Information Provisioning
September 4, 2013
- Fuji Yakuhin, Sanwa Kagaku Launch Gout and Hyperuricemia Treatments Topiloric/Uriadec
September 4, 2013
- President or Head of General Medicine OK’ed Research Grants to 2 Universities: Novartis Exec
September 3, 2013
- Astellas, MSD to Tie Up for SGLT-2 Inhibitor Ipragliflozin
September 3, 2013
- Chugai, Taisho Toyama to Offer Compliance Advantages with Once-Monthly Bonviva
September 3, 2013
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…